Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PLN-101095 + pembrolizumab
- Development stage
- Phase 1
- Lead developer
- Pliant Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
PLN-101095 + pembrolizumab is an investigational combination therapy for adult patients with advanced or metastatic solid tumors who have progressed after prior treatment with pembrolizumab. PLN-101095 is a novel small-molecule inhibitor targeting integrins αvβ1 and αvβ8, designed to modulate the tumor microenvironment and potentially enhance immune recognition. Pembrolizumab is a well-established monoclonal antibody against programmed cell death protein 1 (PD-1), used as an immune checkpoint inhibitor to promote antitumor immune responses. The rationale for this combination is that PLN-101095 may overcome resistance to pembrolizumab by altering the tumor stroma and improving immune infiltration, and the regimen is currently being studied in a dose-escalation Phase 1 clinical trial for patients with solid tumors refractory or relapsed to pembrolizumab therapy[1][2][3][4].
- Other names
- Keytruda + PLN-101095Keytruda + PLN101095PLN-101095 + KeytrudaPLN-101095 + pembrolizumabPLN101095 + KeytrudaPLN101095 + pembrolizumabpembrolizumab + PLN-101095pembrolizumab + PLN101095
02
Targets
αVβ1 (Integrin alpha-V beta-1)αVβ8 (Integrin alpha V beta 8)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on PLN-101095 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PLN-101095 + pembrolizumab.